CJC-1295 / Ipamorelin (GH Pulse)
GH Pulse is a combination sold as one vial: CJC-1295, a copy of growth hormone-releasing hormone, together with Ipamorelin, a selective growth hormone secretagogue. It is studied for growth-hormone-axis support, recovery and body composition.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
At a glance
- CJC-1295 + Ipamorelin (GH Pulse)
- Growth hormone axis
- subcutaneous
- Not yet audited here; the reference library calls it emerging
- Sources differ. See the source
- 20 mg in 3 mL
How much to draw
Full calculator →The reference does not report a single injectable amount for CJC-1295 / Ipamorelin (GH Pulse), so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for CJC-1295 / Ipamorelin (GH Pulse) or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 200-300 mcg of each peptide (CJC-1295 no DAC and Ipamorelin) daily; lower doses of 100-150 mcg typical for first 2-4 weeks before titration | Once dailyStandard: 8-12 weeks on, 4 weeks off; Extended: 16 weeks on, 8 weeks off; Short test: 4-6 weeks on, 4 weeks off | subcutaneous | peptidedosingprotocols.comWhat it saysHide[Source: peptidedosingprotocols.com] |
- Once dailyStandard: 8-12 weeks on, 4 weeks off; Extended: 16 weeks on, 8 weeks off; Short test: 4-6 weeks on, 4 weeks off
- subcutaneous
- peptidedosingprotocols.com
What it saysHide
[Source: peptidedosingprotocols.com]
- For a 20 mg pre-blended vial (10 mg CJC-1295 + 10 mg Ipamorelin): add 3.0 mL bacteriostatic water for a concentration of 6.67 mg/mL total (3.33 mg/mL each peptide); a 200 mcg dose of each peptide = 6 units (0.06 mL) on a U-100 syringe. Alternative fills: 2.0 mL BAC water = 10.0 mg/mL total (5.0 mg/mL each), 200 mcg dose = 4 units (0.04 mL); 2.5 mL BAC water = 8.0 mg/mL total (4.0 mg/mL each), 200 mcg dose = 5 units (0.05 mL). For separate 10 mg vials: add 3.0 mL BAC water to each = 3.33 mg/mL, 200 mcg dose = 6 units (0.06 mL). Step-by-step: inspect the vial; wipe stopper with alcohol prep pad and let dry; draw planned BAC water volume with a sterile syringe; inject BAC water slowly down the inside wall of the vial (do not spray directly onto powder); gently swirl (do not shake) until powder dissolves; label with date and concentration; refrigerate at 35.6-46.4°F (2-8°C) shielded from light; use within 28-30 days; discard if cloudy, discolored, or contaminated.
We have not published an audit on CJC-1295 / Ipamorelin (GH Pulse). Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
One part tells the pituitary gland to make growth hormone, and the other, acting on a different receptor on the same cells, triggers the actual release. Researchers link this to the GHRH receptor for CJC-1295 and the ghrelin receptor (GHSR1a) for Ipamorelin, and a 2002 cell study by Cunha and Mayo suggested the two signals multiply rather than simply add up. Raun et al. 1998 found no meaningful rise in cortisol or ACTH with Ipamorelin, even at 200 times the dose that releases growth hormone. No published human randomised trial has tested the two together at the daily doses used in research planning.
Pairs a GHRH analog (CJC-1295) with a selective GH secretagogue (Ipamorelin) to stimulate pulsatile GH release; studied for recovery and body composition.
Reported side effects
Reported by users: facial flushing or warmth in the first 5-10 minutes after an injection, mild water retention in the first 1-2 weeks that often settles, vivid dreams or deeper sleep, a small rise in hunger 20-30 minutes after Ipamorelin, and mild irritation where it is injected.
Not ruled out: no published human trial has tested this combination at the daily 200-300 mcg planning doses, so these summaries are carried over from the single compounds and from supervised clinic use of similar pairings, and long-term data beyond 90 days is limited even for the single compounds. Growth hormone and IGF-1 encourage cells to divide; tingling or numbness in the hands is described as a sign of too much of either; blood sugar can shift because growth hormone works against insulin; joint pain lasting past the first two weeks is flagged; and FDA review documents named rare allergic-type reactions for both peptides.
Who should avoid it
People with active cancer, a past cancer, or unscreened tumors: growth hormone and IGF-1 encourage cells to divide.
People with pituitary disease: listed as a group that should not use growth-hormone-stimulating peptides, with no further reason given.
People with diabetic retinopathy: listed as a group that should not use growth-hormone-stimulating peptides, with no further reason given.
People with severe kidney disease: listed as a group that should not use growth-hormone-stimulating peptides, with no further reason given.
People who are pregnant or breastfeeding: listed as a group that should not use growth-hormone-stimulating peptides, with no further reason given.
People with diabetes, insulin resistance or pre-diabetes: growth hormone works against insulin, so blood sugar needs close watching.
What gets monitored
IGF-1 baseline before starting, then mid-cycle (week 6-8) and 4 weeks post-cycle. Fasting glucose and HbA1c if metabolic risk factors are present. Joint and hand symptoms throughout the cycle. Optional: thyroid panel if running multi-month plans, since long-term GH stimulation studies have flagged hypothyroidism in a minority of users. (reported by peptidedosingprotocols.com)
Common questions
What does the CJC-1295 and Ipamorelin stack do?
It prompts the body to release more of its own growth hormone through two separate receptor pathways: CJC-1295 at the GHRH receptor on the pituitary, and Ipamorelin at the ghrelin receptor on the same cells. Pharmacology literature describes the combination as synergistic. Neither compound is FDA-approved for any clinical use.
What dose of CJC-1295 and Ipamorelin is reported in research planning?
Reported amounts and schedules for CJC-1295 / Ipamorelin (GH Pulse) differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
Is CJC-1295 paired with Ipamorelin with or without DAC?
Reference material describes the no-DAC form as the one paired with Ipamorelin, because its 30-minute to 2-hour half-life matches Ipamorelin's roughly 2-hour half-life and keeps growth hormone release in natural pulses. The DAC form has a 5.8-8.1 day half-life and gives steady stimulation instead, which sources describe as a poor fit for a pulse-based pairing.
How is the 20 mg blend reconstituted?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
How long is a typical cycle?
Research-planning cycles described in the source run 8-12 weeks on followed by 4 weeks off, with extended plans at 16 weeks on and 8 weeks off. Off periods are described as a way to reduce the chance of the ghrelin receptor becoming less responsive. Long-term safety past 90 days has not been studied for the blend.
What are the main side effects?
Commonly described: brief facial flushing, mild water retention in the first 1-2 weeks, vivid dreams, deeper sleep, and a small hunger bump after Ipamorelin. Flagged as needing attention: carpal tunnel-style tingling, raised fasting glucose, joint pain that persists, and rare allergic-type reactions.
Are CJC-1295 and Ipamorelin FDA-approved?
No. As of June 2026 neither is FDA-approved for any clinical use. Both went onto FDA Category 2 in September 2023, came off in September 2024 after nominations were withdrawn, and were reviewed by PCAC in late 2024, with the FDA recommending against inclusion in 503A Bulks; 2026 discussions are ongoing with no published change.
Is there direct human research on the CJC-1295 and Ipamorelin blend?
No published human randomised trial has tested the combination at the daily 200-300 mcg doses seen online. The case for it rests on each compound's own human pharmacokinetic data plus cell and animal evidence that the two pathways reinforce each other on the same pituitary cell.
Sources
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
Sermorelin is a lab-made peptide that copies the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH). It has been studied in the growth hormone system, including FDA-era trials as a diagnostic agent and as a treatment for growth hormone deficiency in children.
This is a combination of two growth hormone compounds sold in a single vial: tesamorelin, a synthetic copy of growth hormone-releasing hormone, and ipamorelin, a ghrelin mimic that acts as a growth hormone secretagogue. It is sold for research use and is studied in the context of the growth hormone system, visceral fat and recovery.
Epitalon, also spelled epithalon, is a lab-made peptide of four amino acids (Ala-Glu-Asp-Gly), also called AEDG. It is studied mainly for aging, in cells, in animals and in older non-blinded human work on the related pineal extract.
GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.
Glutathione (GSH) is a small molecule built from three amino acids, cysteine, glycine and glutamate, made by nearly every cell and most of all by the liver. It has been studied in people for skin lightening, liver enzymes in fatty liver disease, and Parkinson's disease.
MOTS-c is a short chain of 16 amino acids that cells build from mitochondrial DNA rather than from the DNA in the nucleus. Most of what is known about it comes from cell and animal work on metabolism, exercise capacity and insulin sensitivity.